Jim Tananbaum, Founder of Foresite Capital, Invests in Mindstrong Health for Improved Care for Mental Disorders

In a recent development in the healthcare industry, Mindstrong Health has announced that they have secured a financing of $14 million dollars to assist in the development of their neuropsychiatric treatment and diagnosis platform that they have developed. Some of the top investors include Bergguen Holdings, One Mind Brain Health Impact Fund, Foresite capital, Optum Ventures, besides others.


The founder and the CEO of Mindstrong Health, Dr. Paul Dagum, said that the main aim of the company was to improve the treatments for mental disorders through objective measures just like in chronic diseases. Mindstrong Health has patented their results of intensive clinical research performed over the last four years that reads the interactions done on a Google android or any smartphone and converted into objective measures. According to pelotontherapeutics.com, this new study is set to form a foundation for improving the treatments for mental disorders. The company is expected to share further details about their clinical trials and their results that will help them in delivering better and faster mental health care to patients globally.


Jim Tananbaum, the CEO and the MD of Foresite Capital, in an interview by Business Wire, said that he believes in the methods set by the competent Mindstrong Health’s team and by funding this initiative he is sure that this innovative platform will significantly improve the care provided to people with mental disorders.


Jim Tananbaum is the current CEO and the founder of Foresite Capital that he started back in 201. The company is a healthcare-focused funding companies that healthcare innovations and supply them with capital, networks and the information they need to succeed. Over the years, his company has invested in many successful health care companies and currently has an asset of $1.1 billion.


After graduating from Harvard Medical School, Jim Tananbaum started GelTex Pharmaceuticals that introduced two successful drugs at the cost of about $80 million. The drugs currently make about $1 billion in revenues each year, reveals insidermonkey.com. Jim Tananbaum also started Theravance that currently has a market value of $2.75 billion along with its partner Theravance Biopharma. He continues to invest in healthcare companies that are performing exceptional works and getting results that can transform the healthcare industry for the better.

Oncotarget Contributes to the Fight against Cancer for a Healthier Society


Currently, scientific research provides the best means for battling diseases. With the historical evolution of science, there have been various opportunities for scientists, physicians, and policymakers to generate potent drugs and therapies for various diseases. Since time immemorial, diseases like cancer have been mysterious and challenging to treat in any way. Many people have lost lives battling cancer because most of the time, it is arrested at a late stage where treatment and control of the living growing cells are close to impossible. Read more about Oncotarget at Bioxbio.


That is why many donors and the world as a whole have been camping in research institutes, the internet and banks to contribute in the battle against cancer. One such individual to actively participate in battling cancer, by all means, is Mikhail Blagosklonny. Blagosklonny is the chief editor of Oncotarget, a preview scientific journal, readily available for sharing and disseminating data on cancer and various diseases and infections globally. The role of Oncotarget in the society has been to fight cancer globally through the use of qualified physicians who publish articles on the same.


With the universal drive towards an infection free society increasingly rising over the years, many governments and health sectors have gained momentum in adopting many research-based methodologies like Oncotarget to fight diseases. Being a top-notch peer-reviewed scientific journal for articles, it has embarked on a mission focused on providing answers towards the cure of illness. Following this mission, Oncotarget has increasingly registered massive gains through publishing researchers surrounding advanced and at times strange but helpful discoveries on cancer and various diseases. Read more: https://www.dovepress.com/oncotargets-and-therapy-journal


A recent article in Oncotarget highlighted that although e-cigarettes have for a long period been considered healthy, they have negatively adverse effects to gum. E-cigarettes cause bleeding gums hence, not entirely safe for users. Oncotarget proceeded to publish the new subtype of cervical cancer. Additionally, the journal explained that cancer treatment drugs contributed to weight loss. Being an open and easy to access preview journal, Oncotarget is involved in determining key issues linked to the dissemination of cancer-related information with the aim of offering treatment. With its weekly publications, the journal is bound to reach masses in the society. It, therefore, means that Oncotarget plays a key role in battling cancer and other diseases.

Mikhail Blagosklonny: A Passionate Advocate for Rapamycin

Mikhail Blagosklonny, a Russian scientist, remains one the most ardent advocates of the anti-aging drug called rapamycin. He is a native of St. Petersburg and holds an M.D. in internal medicine as well as a PhD in experimental medicine and cardiology from First Pavlov State Medical University of St. Peterburg. His working experience has added in no small measure to his verse knowledge about cancer and anti-aging therapies having spent time at New York Medical College as an associate professor,Ordway Research Institute as a senior scientist and Roswell Park Cancer Institute where he is currently a professor of oncology since 2009.

Blagosklonny has been carrying out researches on finding new and effective therapies for cancer for several years. He never gave up; he realized in the early 2000s that rapamycin ability to slow tumor growth can also be effective in slowing the aging process. His conviction about the safety and qualities of rapamycin grew to the extend that he tried it himself. When asked if rapamycin is dangerous to human health, he disagree by pointing to the combination of overeating, smoking and driving without belt as posting more danger than rapamycin.To him, rapamycin does as much good as exercising.

Blagosklonny took time to read through all reported side effects of rapamycin and aspirin. He found the later having more side effects. He concluded by saying that rapamycin is yet to show any serious side effects since its approval over 15 years ago.

Mikhail Blagosklonny’s exceptional editorial skills help in propagating his in-dept knowledge about cancer and the adverse effect of aging as well as how these health abnormalities can be curbed. He has over 250 articles, book chapters and reviews to his credit.

A number of top medical journeys and magazine have him on their editorial board.Currently, he occupies the office of the editor-in-chief for Aging, Oncotarget and Cell Cycle. He is an associate editor to Cancer Biology & Therapy. Also, he is on the editorial board of Cell Death & Differentiation.

Many people would have missed out of the good rapamycin does if people with high medical pedigree like Mikhail Blagosklonny did not give their support passionately.

View Mikhail’s profile on Google Scholar.